Clinical trial
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
NCT02559895 is registered in ClinicalTrials.gov with Alder Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2015
- Completion date
- December 31, 2017
- Enrollment
- 898 (actual)
- Sites
- 87
Conditions
As the registry lists them; a condition with its own page is linked.